Here, we found that p53-deficient GBM-SCs, which are more resistant to combined γIR/PI3K/mTOR inhibition than p53-proficient ones [16], retained stem cell marker expression and self-renewal post-treatment. The gene discussed is TP53; the disease is glioblastoma.